1. Introduction

"Impulsivity" describes a pattern of hastily made decisions or behaviors (Evenden, 1999). The term itself invokes a negative connotation, although in certain circumstances, impulsive or spontaneous decisions can be quite functional (Dickman, 1990). From a cognitive and behavioral perspective, impulsivity invites some confusion, as it describes a heterogeneous set of behaviors that manifest in distinct contexts and over distinct timescales (Evenden, 1999). When recognized clinically, impulsivity is most often associated with maladaptive patterns of behavior. In recent years, a broad distinction has been made between ‘motor’ and ‘motivational’ impulsivity (Bari and Robbins, 2013), where motor impulsivity describes inappropriate motor reactions to immediate circumstances or stimulus events on a millisecond timescale, and ‘motivational impulsivity’ characterizes decisions that lack reflection, forethought, patience, and consideration of long-term consequences and reward contingencies (Bari and Robbins, 2013). In human and animal models, these two manifestations of impulsivity are linked to distinct neural mechanisms (Bechara, 2005; Kenner et al., 2010), and can be dissociated using germane cognitive tasks, thus providing a useful framework for classifying clinically observed forms of impulsive behavior.

Emergence of ‘impulsive behaviors’ as a consequence of medical therapy in Parkinson disease (PD) is most often attributed to pharmacologic manipulations of dopamine, which include the use of the dopamine precursor levodopa and dopamine receptor agonists (DAAg) (Weintraub et al., 2010). The administration of DAAg (and to a much
lesser extent, levodopa) has been linked to the development of impulse control disorder (ICD) in approximately 15–20% of patients (Voon et al., 2006; Weintrob et al., 2010). ICD describes excessive interest and participation in certain reward-driven behaviors, expressed in shopping, gambling, eating, sex, and hobbies (Ahlskog, 2011). An understanding of the underlying neurocognitive processes that drive such marked behavioral changes is starting to emerge, but generally remains limited. Determining if ICD behaviors are linked to motor or motivational impulsivity would provide a significant advance in our understanding of the phenomenology of these behaviors. Some studies suggest that, compared to PD patients without ICD, individuals with a history of ICD prefer smaller immediate rewards over larger delayed rewards (i.e., show larger delay discounting effects) (Voon et al., 2010), and those with active ICD symptoms pursue riskier choices (Claassen et al., 2011). Neuroimaging studies highlight differences between patients with and without a history of ICD in mesocorticolimbic circuitry involved in risk decision-making, reward evaluation, and reward learning (Rao et al., 2010; van Eimeren et al., 2010; Voon et al., 2010; Ray et al., 2012). Thus, ICD may represent an emergence of maladaptive ‘appetitive’ behaviors stemming from dopamine-mediated effects on the mesocorticolimbic network.

Few investigations have studied the role of motor impulsivity in ICD patients. We recently investigated differences between PD patients with and without active symptoms of ICD, in the susceptibility to acting on prepotent motor impulses and the proficiency of inhibiting interference from these impulses (Wylie et al., 2012). Contrary to a motor impulsivity hypothesis, patients with active ICD showed a reduced tendency to act incorrectly on strong motor impulses compared to patients without ICD, irrespective of whether they performed under DAAG withdrawal or administration. Additionally, both groups showed similar proficiency in inhibiting interference from impulsive actions when tested withdrawn from DAAG and similar impairment to inhibitory control when tested on medication. These findings (Wylie et al., 2012) provide the motivation to determine if PD-ICD patients have an enhanced susceptibility to acting on motor impulses or reduced ability to inhibit strong motor impulses.

To further investigate the role of motor impulsivity in PD patients with active ICD, we studied the speed at which patients are able to stop already-initiated movements. The gold standard for measuring stopping control is the stop-signal task, which requires participants to make speeded choice reactions to ‘go’ stimuli, but stop reactions upon the infrequent and unpredictable occurrence of a ‘stop’ stimulus, presented within a few hundred milliseconds after the onset of a ‘go’ stimulus (Logan, 1994). The task measures the proficiency (i.e., latency) of interrupting or canceling the preparation of an initiated overt response. Prolonged stop signal reaction time (SSRT) is described in clinical populations characterized by impulsive behaviors and poor inhibitory control, including patients with attention-deficit hyperactivity disorder (Oosterlaan et al., 1998), substance abuse (Monteroasso et al., 2005; Fillmore and Rush, 2002), obsessive–compulsive disorder (Kröger et al., 2004), and schizophrenia (Badcock et al., 2002). Moreover, individuals rating high on impulsive traits also have longer SSRTs (Logan et al., 1997; van den Wildenberg and Christoffels, 2010); thus reduced motor control is directly associated with impulsive behavior.

Here we assessed performance on the stop-signal task in PD patients with active ICD, patients without ICD, and healthy matched controls. All PD patients were taking DAAG, and groups were carefully matched for disease duration, duration of DAAG use, dose of DAAG and levodopa, and motor symptom severity. To determine if the presence of DAAG was critical to stopping effects, the stop-signal task was conducted on optimal dopaminergic medication, and after withdrawing selectively from DAAG. Consistent with previous findings, we predicted that PD patients would show slower SSRTs when compared to healthy controls (Gauggel et al., 2004). Support for the role of motor impulsivity in ICD was expected to manifest as exacerbated slowing of SSRT as compared to PD patients without ICD. Finally, we expected a role for DAAG in stopping control to be revealed by differences in stopping speed on versus temporarily withdrawn from DAAG medication.

## 2. Materials and methods

### 2.1. Participants

Study participants included 24 PD patients and 12 healthy controls. All PD patients met diagnostic criteria based on the UK Brain Bank, and were diagnosed by a Movement Disorder Neurologist (D.C.) (Hughes et al., 1992). All participants were formally screened for global cognitive impairment (Mini-Mental Status Examination, MMSE; Folstein et al., 1975) and depression (Center for Epidemiological Studies–Depression Scale, CES-D; Radloff, 1977)). Motor symptom severity in the On medication state was graded using the UPDRS part III motor score (Fahn et al., 1987). All dopamine medications were converted to levodopa daily dose equivalent (LEDD) using previously reported formulas (Weintrob et al., 2006). See Table 1 for participant details. All participants had normal or corrected-to-normal vision. Participants were screened to ensure that they did not have a history of any neurological condition other than PD, mood disorder such as major depression, history of bipolar affective disorder, schizophrenia, or other psychiatric condition with known effects on cognition, or an untreated or unstable medical condition known to interfere with cognition. Prior to study entry, all participants provided informed consent, which was compliant with standards of ethical conduct in human investigation as regulated by the institutional review board.

All PD patients were taking DAAG, and about half were taking concomitant levodopa therapy. Both patients and a family member completed the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease to screen for the presence or absence of active ICD behaviors (Weintrob et al., 2012). All patients were interviewed by a neurologist (D.C.) and a neuropsychologist (S.W.) to confirm the presence or absence of ICD symptoms based on published criteria (McElroy et al., 1994; American Psychiatric Association, 2000; Grant et al., 2004; Voon et al., 2006). For those meeting ICD criteria, we confirmed the emergence of ICD symptoms subsequent to DAAG initiation. Behaviors included excessive participation, and heightened interest in sexual behaviors (5/12), shopping or buying (5/12), eating (6/12), and time spent on a hobby (9/12). Most patients endorsed at least two of the behaviors (11/12) listed above, and 2 patients endorsed three or more behaviors. PD controls (PD-C) did not meet criteria for any ICD behaviors based on screening and interviewing, and closely matched age.

### Table 1

<table>
<thead>
<tr>
<th>Participant characteristics</th>
<th>HC (n = 12)</th>
<th>PD-IDC (n = 12)</th>
<th>PD-Control (n = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58.5 (6.3)</td>
<td>59.4 (5.5)</td>
<td>60.8 (7.2)</td>
</tr>
<tr>
<td>Education (years)</td>
<td>15.3 (2.9)</td>
<td>17.1 (2.7)</td>
<td>16.3 (2.8)</td>
</tr>
<tr>
<td>Gender (male:female)</td>
<td>6.6</td>
<td>8.4</td>
<td>6.6</td>
</tr>
<tr>
<td>MMSE*</td>
<td>28 (1.7)</td>
<td>29 (1.6)</td>
<td>28.7 (1.6)</td>
</tr>
<tr>
<td>CES-Depression Score</td>
<td>7.0 (6.2)</td>
<td>11.8 (7.7)</td>
<td>8.7 (5)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>–</td>
<td>6.5 (4.7)</td>
<td>6.1 (3.8)</td>
</tr>
<tr>
<td>UPDRS motor score</td>
<td>–</td>
<td>15.9 (6.6)</td>
<td>15.7 (8.3)</td>
</tr>
<tr>
<td>Patients on DA agonist monotherapy</td>
<td>–</td>
<td>5.5</td>
<td>5</td>
</tr>
<tr>
<td>DA agonist duration (years)</td>
<td>–</td>
<td>3.4 (3)</td>
<td>2.7 (2)</td>
</tr>
<tr>
<td>Levodopa dose (mg)</td>
<td>408.2 (349.6)</td>
<td>319.7 (318.9)</td>
<td></td>
</tr>
<tr>
<td>DA agonist dose in LEDD (mg)</td>
<td>–</td>
<td>293.8 (167.4)</td>
<td>200.6 (116.8)</td>
</tr>
<tr>
<td>Total LEDD (mg)</td>
<td>–</td>
<td>618.7 (361.9)</td>
<td>520.3 (314.9)</td>
</tr>
</tbody>
</table>

Values represent mean scores with standard deviations reported in parentheses. Comparisons between Parkinson disease patients with ICD (PD-IDC) and PD patients without ICD (PD-Control) were not statistically significant (p > 0.05).

ICD = impulse control disorder; MMSE = mini-mental state examination; CES = Center for Epidemiological Studies; DA = dopamine; LEDD = levodopa equivalent daily dose.

* Healthy controls completed the Montreal Cognitive Assessment (MoCA) in place of the MMSE.
disease duration, UPDRS motor score, dose and duration of DAAG, and LEDD of the PD-ICD cohort.

PD participants completed two testing visits, once On, and once Off, DAAG therapy (i.e., after a 24 hour withdrawal). The order of sessions was counterbalanced, and levodopa therapy was not altered for either testing session. Healthy controls without PD completed a single testing session.

2.2. Stop Signal Task

We used a manual version of the Stop-Signal task requiring a speeded button press to a series of directional arrows presented one at a time in the center of a computer monitor. Following the display of a small fixation point, a green-colored arrow, pointing to the left or to the right, appeared on the screen, and participants were instructed to make a left or right hand button press based on the direction of the arrow (e.g., left pointing arrow = left button press). Responses were registered by depression of a button (using the thumbs) on the end of handheld grips. Participants were instructed to respond as quickly and as accurately as possible to green arrows (go trials). After a button press was issued or 1200 ms lapsed without a response, the arrow disappeared, and a random interstimulus interval ranging from 1250 to 1750 (in increments of 100 ms) transpired before the onset of the next green arrow. The fixation point remained on the screen during the interstimulus interval.

On 30% of the trials, the green arrow changed color to red shortly after its onset, and participants were instructed to try to stop their button press when the arrow turned red (stop trials). The timing of the delay between the onset of the green arrow and the onset of the color change (stop-signal delay, SSD) was set initially at 200 ms and then adjusted dynamically across stop trials using a staircase-tracking procedure that controlled for the success of stopping (i.e., inhibition probability; (Levitt, 1971)). Following a successful stop, the SSD for the next stop trial was delayed by 50 ms, thus making it more difficult to stop. Following an unsuccessful stop, the SSD for the next stop trial was shortened by 50 ms, effectively making it easier to stop. These adjustments ensured that responses were successfully inhibited in approximately half of the stop trials, a requirement for estimating stop-signal reaction time that compensates for individual differences in choice reaction time to the go arrows (Band et al., 2003). SSRT was computed using the integration method described by Logan et al. (1984). Participants first completed a block of 60 practice trials. Next, they completed 5 blocks of 60 experimental trials, yielding 90 total stop trials, which is more than adequate for producing a reliable estimate of SSRT (Band et al., 2003).

2.3. Statistical techniques and design

Extreme RT values, either excessively fast (so-called anticipatory errors; <150 ms) or slow (>3 standard deviations), were removed from the analysis using a combination of statistical procedures (e.g., value > 3 standard deviations above the mean) followed by visual inspection to ensure that only extreme outliers were excluded. On average, these procedures led to the exclusion of less than 0.5% of trials per subject. Three key dependent measures were computed: mean reaction time to correct go trials (GoRT), mean accuracy to go trials (GoAcc), and stop-signal reaction time (SSRT). The probability of successful inhibition on stop trials was computed to verify that the tracking algorithm approximated the targeted 50% stop success rate (Band et al., 2003). An additional measure, the mean RT for unsuccessfully inhibited responses on stop trials (i.e., signal-respond RT), was computed and compared to mean go RT to verify a key assumption of the race model regarding the independence of the go and stop processes that is required to estimate stopping latency (SSRT) reliably (Logan, 1994); specifically, mean signal-respond RT should be shorter than mean GoRT.

We conducted three primary analyses. First, healthy controls without PD were compared to both PD groups in the On medication state. Previous work has shown that stopping is slowed in medicated PD patients (Gauggel et al., 2004). This analysis included a single between-subjects factor of Group (PD-C, PD-ICD, HC). The dependent measures were analyzed separately using repeated-measures analysis of variance techniques (Huynh–Feldt adjustments for violations of sphericity) to determine the effect of Group on choice reaction time and accuracy (GoRT, GoAcc) and on speed of inhibition (SSRT). Next, we compared the two groups of PD patients On and Off DAAG. The primary design included one between-subjects factor, ICD Group (PD-C, PD-ICD), and one within-subjects factor, Agonist State (On, Off). The dependent measures were analyzed separately using repeated-measures analysis of variance techniques (Huynh–Feldt adjustments for violations of sphericity) to determine the main and interactive effects of Group and Agonist State on choice reaction time and accuracy (GoRT, GoAcc) and on stopping proficiency (SSRT). Because half of the PD patients were taking levodopa co-therapy, a third analysis included an additional between-subjects factor, Levodopa Status (sine L-Dopa, cum L-Dopa), to capture any influence of levodopa co-therapy on key dependent measures.

3. Results

3.1. Comparisons between healthy controls (HC) and medicated PD patients

3.1.1. Choice reaction performance (RT and accuracy on Go Trials) Mean RT and accuracy rates to go arrows (Fig. 1a) did not differ among HC and PD subgroups (Group: RT—$F(2,33) = 5.28$, $p = .594$; Accuracy—$F(2,33) = 123$, $p = .885$). All groups showed high accuracy rates to go arrows.

3.1.2. Stop-signal reaction time (SSRT) The estimate of SSRT requires verification that (a) stopping accuracy approximated 50%, and (b) mean RT for failed stop trials is shorter than mean RT for go trials. Both conditions were satisfied across groups. Specifically, stopping accuracy was similar and near 50% for all groups (HC = 49.2%, PD-C = 50.8%, PD-ICD = 50.5%) (Group, $F(2,33) = .248$, $p = .782$). Overall, mean signal-respond RTs were similar across groups (Group, $F(2,33) = .811$, $p = .453$), and an average of 84 ms faster than mean RTs for go trials (Trial Type (Go, Failed Stop), $F(1,33) = 79.149$, $p = .001$), which did not differ among groups (Group × Trial Type, $F(2,33) = 637$, $p = .535$). These analyses confirm the success of the tracking algorithm and the reliability of the estimate of stopping latency (SSRT) across groups. Mean SSRTs for each group are shown in Fig. 1b, which reveals a significant effect of Group on SSRT (Group, $F(2,33) = 4.411$, $p = .02$). Post-hoc comparisons referenced to the HC group (using Dunnett’s post hoc test) revealed that PD-ICD patients stopped faster than HCs ($p = .036$), whereas PD-C patients showed similar SSRTs compared to HCs ($p = .966$). See Table 2 for illustration of these findings.

3.2. Comparisons between PD-ICD and PD-C groups On and Off DAAG

3.2.1. Choice reaction performance (RT and accuracy on Go Trials) Mean RT and accuracy rates to go arrows (Fig. 2a) did not differ between PD groups (ICD Group: RT—$F(1,22) = .379$, $p = .545$; Accuracy—$F(1,22) = 1.300$, $p = .267$), but between On and Off DAAG medication states (Agonist State: RT—$F(1,22) = .858$, $p = .364$; Accuracy—$F(1,22) = .574$, $p = .457$). Moreover, the groups showed similar patterns of mean RT and accuracy rates On and Off DAAG medication (ICD Group × Agonist State: RT—$F(1,22) = .103$, $p = .751$; Accuracy—$F(1,22) = .399$, $p = .534$).

3.2.2. Stop-signal reaction time (SSRT) We first verified the reliability of the estimate of SSRT. Specifically, stopping accuracy was similar and near 50% when On (50.6%) or Off
(49.0%) DAAg (Agonist State, F(1,22) = .858, p = .364), and both groups showed similar stopping accuracy that approximated 50% (PD-C: 50.0%, PD-ICD: 49.7%) (ICD Group, F(1,22) = .092, p = .764), irrespective of DAAg state (ICD Group × Agonist State, F(1,22) = .000, p = 1.00). Additionally, mean RTs for failed stop trials (456 ms) were 80 ms faster than mean RTs for go trials (536 ms) (Trial Type, F(1,22) = 80.68, p < .001). This pattern was preserved On or Off DAAg (Agonist State × Trial Type, F(1,22) = 2.015, p = .170), and independent of ICD group status (ICD Group × Trial Type, F(1,22) = .036, p = .852), irrespective of the DAAg state (ICD Group × Agonist State × Trial Type, F(1,22) = .149, p = .703). These analyses confirm the success of the tracking algorithm and the reliability of the estimate of stopping latency across PD subgroups and DAAg states (SSRT).

Mean SSRTs for each group and medication state are presented in Fig. 2b. Mean SSRT was similar when patients were On or Off DAAg (Agonist State, F(1,22) = 1.243, p = .277). However, the PD-ICD group showed faster SSRT (i.e., more proficient inhibition) compared to the PD-C group (ICD Group, F(1,22) = 5.558, p = .008), a pattern that was preserved across DAAg states (ICD Group × Agonist: F(1,22) = 0.188, p = .669). See Table 2 for illustration of these findings.

### 3.3. Effects of levodopa co-therapy on Go and Stop measures

An equivalent, but slight, majority (58%) of patients in both groups were taking both levodopa and DAAg dual therapy and remained on their usual dose of levodopa for both testing sessions. The remaining 42% of patients, who were taking DAAg monotherapy, were tested On and Off medication. Thus, a difference in performance between these subgroups might relate to the role of levodopa. To examine this effect, we included an additional between-subjects factor, Levodopa Status (sine L-Dopa, cum L-Dopa), in the analysis comparing PD-ICD and PD-C subgroups. None of the aforementioned patterns regarding main or interactive effects of ICD Group and DAAg State on any of the dependent measures changed; thus we only describe results pertaining to the effects of Levodopa Status.

#### 3.3.1. Choice reaction performance (RT and accuracy on Go Trials)

Mean RT and accuracy rates on go trials did not differ between patients taking (523 ms, 98.1%) and not taking (554 ms, 98.5%) L-Dopa (Levodopa Status: RT—F(1,20) = 0.654, p = .428; Accuracy—F(1,20) = .851, p = .367), irrespective of ICD status: (PD-ICD: sine L-Dopa = 559 ms, 98.3%; cum L-Dopa = 540 ms, 98.6%) (PD-C: sine L-Dopa = 550 ms, 98.6%; cum L-Dopa = 507 ms, 97.6%) (Levodopa Status × ICD Group: RT—F(1,20) = .093, p = .763; Accuracy—F(1,20) = 2.297, p = .145). However, the presence of levodopa significantly influenced the effect of DAAg on RTs, but not accuracy rate (Levodopa Status × Agonist State: RT—F(1,20) = 6.211, p = .022; Accuracy—F(1,20) = .017, p = .908). The interaction on RT is illustrated in Fig. 3a. Patients taking DAAg monotherapy showed a significant speeding of RT On compared to Off. The opposite effect was observed in dual-therapy patients; the addition of DAAg to levodopa caused a slowing of RT compared to when these patients performed only On levodopa. Notably, these patterns on RT and on accuracy rates did not vary with ICD status (Levodopa Status × Agonist State × Group: RT—F(1,20) = .008, p = .928; Accuracy—F(1,20) = 2.484, p = .131).

#### 3.3.2. Stop-signal reaction time (SSRT)

Levodopa status did not alter the probability of stopping success nor the pattern of faster RTs for unsuccessful stop trials compared to RTs for go trials (all ps > .10), indicating that SSRT was estimated reliably and uniformly across all between-subject groups. Mean SSRT was marginally, but non-significantly, faster among patients taking (207 ms) compared to not taking (228 ms) levodopa dual therapy (Fig. 3b) (Levodopa Status, F(1,20) = 3.050, p = .096), a pattern that remained unchanged across ICD groups (PD-ICD: sine L-Dopa = 216 ms, cum L-Dopa = 184 ms; PD-C: sine L-Dopa = 240 ms, cum L-Dopa = 230 ms) (Levodopa Status × ICD Group, F(1,20) = .819, p = .376), DAAg state (Off Agonist: sine L-Dopa = 224 ms, cum L-Dopa = 202 ms; On Agonist: sine L-Dopa = 233 ms, cum L-Dopa = 212 ms) (Levodopa Status × Agonist State, F(1,20) = .006, p = .938), and the combination of these factors (Levodopa Status × Agonist State × ICD Group, F(1,20) = 2.059, p = .167). See Fig. 3 and Table 3 for an illustration of these findings.

### 4. Discussion

The goal of this study was to directly test the motor impulsivity hypothesis of ICD in PD by investigating, for the first time, the speed with which patients with ICD inhibit initiated motor actions. The stop-signal task is a gold standard in measuring the speed of motor inhibition,
and prolonged stopping has been directly linked to impulsive traits and patient groups. In PD-patients with moderate to severe disease severity, SSRT is typically delayed (Gauggel et al., 2004). One study demonstrated that dopamine therapy has minimal influence on SSRT, compared to a dopamine withdrawn state, although levodopa and DAaG effects were treated collectively rather than separately (Obeso et al., 2011). In contrast, bilateral subthalamic nucleus (STN) deep brain stimulation appears to improve stopping control (van den Wildenberg et al., 2006). These studies indicate that changes in stopping control and, inferentially, susceptibility to motor impulsivity are vulnerable cognitive processes in PD.

Stopping RTs (SSRTs) and choice RTs were reliably measured in PD groups with and without ICD and in healthy controls. Choice RTs and accuracy to go stimuli did not differ among the ICD and non-ICD PD groups, suggesting that processes involved in the initiation and execution of speeded reactions were very similar across the groups. In striking contrast to the motor impulsivity hypothesis of ICD, patients with active ICD were significantly faster at stopping initiated motor actions compared to healthy controls and PD patients without ICD. The transient withdrawal from DAaG did not alter the SSRT advantage in inhibitory motor control for patients with ICD. In fact, SSRT did not vary whether PD patients, irrespective of ICD status, performed the stop-signal task on or withdrawn from DAaG. Finally, whether patients were or were not taking levodopa co-therapy had no influence on SSRTs, although the effect of DAaG on choice RT was strongly influenced by levodopa co-therapy.

4.1. Faster stop-signal reaction time in PD-ICD: why?

These results expand evidence that ICD does not involve fundamental changes in the ability to inhibit motor behavior, a finding that also calls into question that PD-ICD involves fundamental deficits in motor impulsivity. Rather, PD-ICD patients show more proficient stopping control, a finding that is quite consistent with previous work showing that PD patients with ICD, compared to patients without ICD, showed reduced susceptibility to acting on strong motor impulses elicited in a response conflict task (Wylie et al., 2012). Together, these findings suggest the contrary view that patients with active ICD are more...
proficient at inhibiting both intended and impulsive motor actions. How might this be explained? First, animal studies and human imaging work show that higher D2-like receptor availability in the dorsal striatum is associated with faster SSRTs (Eagle and Robbins, 2003; Chahremeti et al., 2012) and administration of agonists that target these receptors also speeds SSRT (Nandam et al., 2013). In contrast, D2-like receptor antagonism slows SSRT, and self-reported impulsivity has been linked to lower SSRTs and reduced midbrain D2-like receptor availability (Lee et al., 2009; Logan et al., 1997; Buckholtz et al., 2010). Thus, the finding that PD patients with active ICD show markedly faster SSRTs than PD and healthy controls may directly reflect a fundamental change or difference in D2-like receptor profiles in dorsal striatum, subsequent to chronic dopamine agonist use. Based on the aforementioned patterns, it could be hypothesized that PD patients with ICD have an increased D2 receptor availability that leads to faster, rather than slower, inhibitory motor control. Notably, no evidence to date has suggested differences in dopamine D2 receptor polymorphisms among those with and without ICD, even though specific variations in dopamine genetics have been linked to individual differences in SSRT in healthy adults ((Mueller et al., 2011), and see (Vallelunga et al., 2012) for study of dopamine genetics in PD patients with and without ICD). This will be an important area for future investigations.

A second explanation can be deduced from the assertion that dopaminergic activity at D2 receptors in dorsal striatum facilitates the braking of motor actions (Eagle et al., 2011). Moreover, a right lateralized network inclusive of specific prefrontal (right inferior cortex, pre-supplementary motor area) and basal ganglia (subthalamus, mammillary bodies) structures is proposed to mediate inhibitory action control (Ridderinkhof et al., 2004). A recent study reported that, compared to non-ICD patients, PD patients with ICD show reduced dopamine transporter binding in the right striatum (Voon et al., 2014). Thus, ICD patients may experience diminished dopamine clearance in right basal ganglia, the effect of which may be the facilitation of inhibitory control via D2 activation. Future studies might examine how striatal dopamine receptors and function, particularly in the right hemisphere, are differentially modified by chronic dopamine therapy, and the development of ICD.

4.2. Levodopa and dopamine agonist effects on motor control

The acute administration of DAAG did not influence SSRTs compared to a temporarily withdrawn state. Animal studies of the stop task have found modulation of SSRT by dopamine D2 agonism (faster SSRT) and antagonism (slower SSRT). One difficulty in equating prior work with the current study is the fact that PD patients were treated with DAAG chronically, which likely produces different dopamine receptor and neurochemical effects. Our patients were also withdrawn for a minimum of 24 h, which may not have been sufficient to fully eliminate DAAG. A more effective approach might consider the acute and chronic effects of DAAG medication on SSRT in de novo PD patients who are tracked longitudinally subsequent to initiating DAAG or levodopa therapy.

The acute administration of dopamine medication did impact choice RTs (i.e., GoRTs) in PD patients, and the direction of the effect depended on concurrent levodopa use. Among patients taking only DAAG monotherapy, choice RTs were significantly faster when patients performed under the influence of DAAG compared to the withdrawn state. In contrast, in patients taking levodopa co-therapy, DAAG slowed choice RTs in patients taking levodopa. To the best of our knowledge, we have not seen this interaction reported previously, and very few studies have directly compared the levodopa and DAAG and their interactions on specific cognitive processes. Dopamine stimulation, via either mechanism, is typically associated with faster RTs, whereas dopamine antagonism usually slows RT (Eagle et al., 2007). The current findings raise the possibility that levodopa (D1/D2 effects) and receptor agonists (D2/D3 effects) interact in complex ways, possibly by shifting the balance between the putative “go” pathway (i.e., D1-mediated direct pathway) and the “stop” pathway (i.e., D2-mediated indirect pathway). We suspect that the nature of this interaction is likely to depend on several factors, including an individual’s dopamine genetic polymorphism, baseline reaction time Off medications, and relative doses of DAAG and levodopa. It will be important for future work to understand these effects to optimize medication effects, and facilitate (rather than impede) RT.

4.3. Stop signal reaction time in Parkinson disease

One notable finding in the current study is the absence of SSRT differences between PD controls and healthy controls. Previous studies have generally confirmed a stopping speed deficit in PD patients (Gauggel et al., 2004). The difference between this and the Gauggel et al. study is the sample of PD patients—patients in our study were earlier in the disease course (6 versus 9 year duration of symptoms), and less severe (Hoehn and Yahr 1–2 versus 2.6). We speculate that global stopping speed deficits develop in more moderate stages of PD when dopamine degeneration is more likely to disrupt putative cognitive circuitries. Again, longitudinal studies to detect the emergence of inhibitory control deficits are desperately needed.

A second noteworthy issue is that PD patients with ICD included in the current investigation were all studied before any reduction or discontinuation of DAAG medication was initiated, and were actively symptomatic with ICD symptoms. This differs from many studies in the literature that investigated PD patients with a history of ICD, but who were no longer displaying active symptoms, or on the dosage of the offending medication. Few, if any, studies have investigated changes in cognitive functioning in ICD patients tested during active ICD and after DAAG discontinuation. Whether the SSRT advantage remains or dissipates following chronic withdrawal from DAAG may offer insights to acute and chronic effects of DAAG therapy.

4.4. Are PD patients with impulsive and compulsive behaviors really impulsive?

In light of past studies in PD ICD, the nature of impulsivity that develops in a subset of PD patients taking DAAG appears to weigh in favor of a ‘motivational,’ or ‘affective’ account of impulsivity rather than a motor impulsivity account. This distinguishes the nature of impulsivity in PD-ICD from that of other patient groups who show clear impulsive motor behavior (e.g., ADHD, OCD, substance abuse). Previous imaging and behavioral studies of ICD have focused on mesocorticolimbic-ventral striatal network in response to dopamine therapy. These studies link baseline differences in ventral striatal D2-like receptors, to exaggerated mesocorticolimbic dopamine release in patients with ICD (Rao et al., 2010; O’Sullivan et al., 2011). Previous work has also linked ICD with enhanced risk-taking and reward behavior emphasizing alterations to mesocorticolimbic function (Claassen et al., 2011). Future work must reconcile the emergent dysfunction of
risk-taking and reward and associated mesocorticlimbic circuitries and the apparent enhancement of motor inhibitory control.

**Funding**

Funding provided by NIH/NINDS K23NS080988 and the American Academy of Neurology to Dr. Claassen, and NIH/NIA K23AG028750 to Dr. Wylie.

**Acknowledgments**

The authors would like to thank Dr. G. Frederick Woolen for their guidance on patient recruitment and study design.

**References**


